Compositions and methods for expression of IL-12 and IL-1RA
AssigneeReplicate Bioscience, Inc.
InventorsNathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.
Claims19
A nucleic acid construct comprising a nucleic acid sequence encoding a modified alphavirus genome or self-replicating RNA (srRNA) obtained from an alphavirus genome or srRNA, wherein said modified alphavirus genome or srRNA is produced by replacing at least a portion of the nucleic acid sequence encoding the viral structural proteins of the alphavirus genome or srRNA with a coding sequence for a polypeptide construct comprising:
- a) a coding sequence for a p35 subunit of interleukin 12 (p35 or IL-12A) or a functional variant thereof;
- b) a coding sequence for a p40 subunit of interleukin 12 (p40 or IL-12B) or functional variant thereof;
- and c) a coding sequence for an interleukin-1 receptor antagonist (IL-1RA) or a functional variant thereof, wherein the coding sequences for IL-12A, IL-12B, and IL-1RA, or functional variants thereof, are operably linked to one another, and wherein the coding sequences for IL-12A, IL-12B, and IL-1RA express protein that is functional in a bioactivity assay, and wherein the nucleic acid sequence has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.